AELIS Fundamental Analysis - AELIS FARMA SAS

Name: AELIS FARMA SAS (AELIS) Stock
Brand: AELIS FARMA SAS
Rating: 4 (3 reviews)

Fundamental Rating

AELIS gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 77 industry peers in the Biotechnology industry. AELIS has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, AELIS is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

AELIS had negative earnings in the past year.

AELIS had a negative operating cash flow in the past year.

In the past 5 years AELIS reported 4 times negative net income.

AELIS had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

AELIS's Return On Assets of -52.61% is on the low side compared to the rest of the industry. AELIS is outperformed by 68.00% of its industry peers.

Looking at the Return On Equity, with a value of -134.05%, AELIS is in line with its industry, outperforming 42.67% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-52.61%
ROE	-134.05%
ROIC	N/A

ROA(3y)-31.08%

ROA(5y)-24.2%

ROE(3y)-61.94%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

AELIS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

AELIS does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, AELIS has more shares outstanding

AELIS has more shares outstanding than it did 5 years ago.

The debt/assets ratio for AELIS is higher compared to a year ago.

2.2 Solvency

A Debt/Equity ratio of 0.74 indicates that AELIS is somewhat dependend on debt financing.

Looking at the Debt to Equity ratio, with a value of 0.74, AELIS is in line with its industry, outperforming 45.33% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0.74
Debt/FCF	N/A
Altman-Z	N/A

ROIC/WACCN/A

WACC7.33%

2.3 Liquidity

A Current Ratio of 3.18 indicates that AELIS has no problem at all paying its short term obligations.

The Current ratio of AELIS (3.18) is better than 66.67% of its industry peers.

AELIS has a Quick Ratio of 3.18. This indicates that AELIS is financially healthy and has no problem in meeting its short term obligations.

With a decent Quick ratio value of 3.18, AELIS is doing good in the industry, outperforming 68.00% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	3.18
Quick Ratio	3.18

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

AELIS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -13.00%.

Looking at the last year, AELIS shows a very negative growth in Revenue. The Revenue has decreased by -94.09% in the last year.

The Revenue for AELIS have been decreasing by -33.42% on average. This is quite bad

EPS 1Y (TTM)-13%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-16.8%

Revenue 1Y (TTM)-94.09%

Revenue growth 3Y-33.42%

Revenue growth 5YN/A

Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, AELIS will show a very strong growth in Earnings Per Share. The EPS will grow by 146.58% on average per year.

AELIS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 88.24% yearly.

EPS Next Y-131.58%

EPS Next 2Y70.14%

EPS Next 3Y146.58%

EPS Next 5YN/A

Revenue Next Year-52.86%

Revenue Next 2Y33.1%

Revenue Next 3Y88.24%

Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

AELIS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

With a Price/Forward Earnings ratio of 6.57, the valuation of AELIS can be described as very cheap.

Based on the Price/Forward Earnings ratio, AELIS is valued cheaply inside the industry as 98.67% of the companies are valued more expensively.

Compared to an average S&P500 Price/Forward Earnings ratio of 34.46, AELIS is valued rather cheaply.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	6.57

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as AELIS's earnings are expected to grow with 146.58% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y70.14%

EPS Next 3Y146.58%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

AELIS does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

AELIS FARMA SAS

EPA:AELIS (11/21/2025, 7:00:00 PM)

1.15

+0.02 (+2.22%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)N/A N/A

Earnings (Next)N/A N/A

Inst Owners25.12%

Inst Owner ChangeN/A

Ins Owners17.74%

Ins Owner ChangeN/A

Market Cap15.77M

Revenue(TTM)446.00K

Net Income(TTM)-8.20M

Analysts84.44

Price Target11.22 (875.65%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	6.57
P/S	35.35
P/FCF	N/A
P/OCF	N/A
P/B	2.58
P/tB	2.66
EV/EBITDA	N/A

EPS(TTM)-0.6

EYN/A

EPS(NY)0.18

Fwd EY15.23%

FCF(TTM)-0.55

FCFYN/A

OCF(TTM)-0.55

OCFYN/A

SpS0.03

BVpS0.45

TBVpS0.43

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-52.61%
ROE	-134.05%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-31.08%

ROA(5y)-24.2%

ROE(3y)-61.94%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score2

Asset Turnover0.03

Health

		Industry Rank	Sector Rank
Debt/Equity	0.74
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	11.44%
Cap/Sales	6.95%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	3.18
Quick Ratio	3.18
Altman-Z	N/A

F-Score2

WACC7.33%

ROIC/WACCN/A

Cap/Depr(3y)106.33%

Cap/Depr(5y)205.47%

Cap/Sales(3y)3.89%

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-13%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-16.8%

EPS Next Y-131.58%

EPS Next 2Y70.14%

EPS Next 3Y146.58%

EPS Next 5YN/A

Revenue 1Y (TTM)-94.09%

Revenue growth 3Y-33.42%

Revenue growth 5YN/A

Sales Q2Q%-100%

Revenue Next Year-52.86%

Revenue Next 2Y33.1%

Revenue Next 3Y88.24%

Revenue Next 5YN/A

EBIT growth 1Y-6.9%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-115.71%

EBIT Next 3Y152.58%

EBIT Next 5YN/A

FCF growth 1Y40.9%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y40.71%

OCF growth 3YN/A

OCF growth 5YN/A

AELIS FARMA SAS / AELIS.PA FAQ

What is the fundamental rating for AELIS stock?

ChartMill assigns a fundamental rating of 2 / 10 to AELIS.PA.

What is the valuation status for AELIS stock?

ChartMill assigns a valuation rating of 3 / 10 to AELIS FARMA SAS (AELIS.PA). This can be considered as Overvalued.

How profitable is AELIS FARMA SAS (AELIS.PA) stock?

AELIS FARMA SAS (AELIS.PA) has a profitability rating of 0 / 10.

How financially healthy is AELIS FARMA SAS?

The financial health rating of AELIS FARMA SAS (AELIS.PA) is 3 / 10.

AELIS FARMA SAS (AELIS.PA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

AELIS FARMA SAS / AELIS.PA FAQ

What is the fundamental rating for AELIS stock?

What is the valuation status for AELIS stock?

How profitable is AELIS FARMA SAS (AELIS.PA) stock?

How financially healthy is AELIS FARMA SAS?